Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 55154-7883

15 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 55154-7883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Bc153659 2091 4682 A63b 8735e1146bac 14)

Structural Formula (Bc153659 2091 4682 A63b 8735e1146bac 14)
Chemical structure of Donepezil Hydrochloride showing its molecular arrangement with methoxy groups, a piperidine ring, and a benzyl moiety bound to hydrochloride.*
FDA Label Image

Figure 1 (Bc153659 2091 4682 A63b 8735e1146bac 13)

Figure 1 (Bc153659 2091 4682 A63b 8735e1146bac 13)
A line graph depicting ADAS-cog change from baseline over 30 weeks of drug treatment with donepezil hydrochloride tablets at 10 mg/day and 5 mg/day compared to placebo. The y-axis shows mean change from baseline (±SE), with directions indicating clinical improvement and decline. The x-axis shows weeks of treatment, including a placebo period.*
FDA Label Image

Figure 2 (Bc153659 2091 4682 A63b 8735e1146bac 12)

Figure 2 (Bc153659 2091 4682 A63b 8735e1146bac 12)
A cumulative percentage plot showing change from baseline in ADAS-cog scores for Donepezil Hydrochloride Tablets at 5 mg/day and 10 mg/day doses versus placebo. The x-axis represents change from baseline, and the y-axis shows the cumulative percentage of patients. The graph includes vertical markers at 7 points, 4 points, and no change, with a table detailing treatment group percentages achieving specific ADAS-cog changes (-7, -4, 0).*
FDA Label Image

Figure 3 (Bc153659 2091 4682 A63b 8735e1146bac 11)

Figure 3 (Bc153659 2091 4682 A63b 8735e1146bac 11)
A bar chart displaying the percentage of patients categorized by CIBIC-plus Rating levels for Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo. The x-axis shows ratings from Markedly Improved to Markedly Worse, while the y-axis represents the percentage of patients. Three color-coded bars compare patient outcomes across the ratings.*
FDA Label Image

Figure 4 (Bc153659 2091 4682 A63b 8735e1146bac 10)

Figure 4 (Bc153659 2091 4682 A63b 8735e1146bac 10)
Line graph depicting the mean change from baseline in ADAS-cog scores over 12 weeks of treatment with Donepezil Hydrochloride Tablets at 5 mg/day and 10 mg/day, compared to placebo. The y-axis shows changes indicating clinical improvement or decline, while the x-axis represents weeks of drug treatment. The graph includes error bars for standard error and highlights different response patterns between the donepezil doses and placebo.*
FDA Label Image

Figure 5 (Bc153659 2091 4682 A63b 8735e1146bac 09)

Figure 5 (Bc153659 2091 4682 A63b 8735e1146bac 09)
A cumulative percentage of patients graph comparing Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows change from baseline, with annotations for 7-point, 4-point, and no change markers, while the y-axis shows cumulative percentage of patients. An inset table presents percentage changes in ADAS-cog scores at -7, -4, and 0 for each treatment group.*
FDA Label Image

Figure 6 (Bc153659 2091 4682 A63b 8735e1146bac 08)

Figure 6 (Bc153659 2091 4682 A63b 8735e1146bac 08)
A bar chart showing the distribution of patients' CIBIC-plus ratings comparing Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo groups. The x-axis lists categories from Markedly Improved to Markedly Worse, and the y-axis shows the percentage of patients. The chart compares response levels among the three groups.*
FDA Label Image

Figure 7 (Bc153659 2091 4682 A63b 8735e1146bac 07)

Figure 7 (Bc153659 2091 4682 A63b 8735e1146bac 07)
A line graph showing SIB change from baseline mean (±SE) over 6 months of drug treatment comparing Donepezil Hydrochloride Tablets 10 mg/day to placebo. The graph indicates clinical improvement with Donepezil and clinical decline with placebo from baseline.*
FDA Label Image

Figure 8 (Bc153659 2091 4682 A63b 8735e1146bac 06)

Figure 8 (Bc153659 2091 4682 A63b 8735e1146bac 06)
A cumulative percentage graph comparing Donepezil Hydrochloride Tablets 10 mg/day to placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, and the y-axis shows the cumulative percentage of patients. Two curves represent patient response distributions for donepezil and placebo groups.*
FDA Label Image

Figure 9 (Bc153659 2091 4682 A63b 8735e1146bac 05)

Figure 9 (Bc153659 2091 4682 A63b 8735e1146bac 05)
Line graph depicting the change from baseline in ADCS-ADL-Severe scores over six months for patients on Donepezil Hydrochloride tablets 10 mg/day compared to placebo. The vertical axis represents mean change from baseline, with clinical improvement upward and decline downward. The horizontal axis shows months of treatment at 0, 3, and 6 months.*
FDA Label Image

Figure 10 (Bc153659 2091 4682 A63b 8735e1146bac 04)

Figure 10 (Bc153659 2091 4682 A63b 8735e1146bac 04)
A cumulative percentage of patients graph comparing Donepezil Hydrochloride Tablets 10 mg/day to placebo. The X-axis represents ADCS-ADL change from baseline, while the Y-axis shows the cumulative percentage of patients. Two curves are displayed: one with filled circles for Donepezil Hydrochloride 10 mg/day and one with open squares for placebo, depicting patient response distribution.*
FDA Label Image

Logo (Bc153659 2091 4682 A63b 8735e1146bac 03)

FDA Label Image

Logo 1 (Bc153659 2091 4682 A63b 8735e1146bac 02)

FDA Label Image

5mg Bag Label (Cb092ac4 5569 4fbf 88bd 8b3037a946fb 01)

5mg Bag Label (Cb092ac4 5569 4fbf 88bd 8b3037a946fb 01)
Donepezil Hydrochloride Tablets USP 5 mg label for a 10-tablet unit dose package. The label includes dosage form as film-coated tablets, storage instructions at controlled room temperature, a warning that the package is not child-resistant and intended for institutional use, and patient information instructions. It also lists packaging and distribution by Major Pharmaceuticals and Cardinal Health with relevant addresses and NDC numbers.*
FDA Label Image

10mg Bag Label (Cb092ac4 5569 4fbf 88bd 8b3037a946fb 00)

10mg Bag Label (Cb092ac4 5569 4fbf 88bd 8b3037a946fb 00)
Donepezil Hydrochloride Tablets USP 10 mg, film-coated tablets, package of 10 tablets. Label includes dosage form and strength, storage instructions, warnings, and distributor information. Distributed by Cardinal Health 107, LLC and packaged by Major Pharmaceuticals, Indianapolis, IN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.